< 生产厂家价格 >

2-氨基-3-(4-羟基-3-甲氧基苯基)丙酸

2-氨基-3-(4-羟基-3-甲氧基苯基)丙酸用途

3-O-甲基-DL-DOPA是一种存在于脑脊液中的内源性代谢产物,可用于研究癫痫、嘌呤核苷磷酸化酶缺乏症和芳香L氨基酸脱羧酶缺乏症[1][2][3][4]。

点击显示

2-氨基-3-(4-羟基-3-甲氧基苯基)丙酸名称

[ CAS 号 ]:
7636-26-2

[ 中文名 ]:
2-氨基-3-(4-羟基-3-甲氧基苯基)丙酸

[ 英文名 ]:
(DL)-3-O-Methyldopa

[中文别名 ]:

[英文别名 ]:

3-Methoxytyrosine
3-Methoxy-D,L-tyrosine
3-Methoxy-tyrosine
Tyrosine, 3-methoxy-
3-METHOXY-DL-TYROSINE
UNII:SO86T1OB2P
3-O-Methyldopa

2-氨基-3-(4-羟基-3-甲氧基苯基)丙酸生物活性

[ 描述 ]:

3-O-甲基-DL-DOPA是一种存在于脑脊液中的内源性代谢产物,可用于研究癫痫、嘌呤核苷磷酸化酶缺乏症和芳香L氨基酸脱羧酶缺乏症[1][2][3][4]。

[ 相关类别 ]:

研究领域 >> 神经疾病

[体外研究]

内源性代谢产物被定义为《京都基因和基因组百科全书》注释为我们基因组中约1900种代谢酶的底物或产物。在文献正文中很清楚,许多这些代谢产物都具有毒性[1]。

[参考文献]

[1]. Lee N, et al. Endogenous toxic metabolites and implications in cancer therapy. Oncogene. 2020 Aug;39(35):5709-5720.

[2]. Darin N, et al. Mutations in PROSC Disrupt Cellular Pyridoxal Phosphate Homeostasis and Cause Vitamin-B6-Dependent Epilepsy. Am J Hum Genet. 2016 Dec 1;99(6):1325-1337.

[3]. Ormazabal A, et al. Pyridoxal 5'-phosphate values in cerebrospinal fluid: reference values and diagnosis of PNPO deficiency in paediatric patients. Mol Genet Metab. 2008 Jun;94(2):173-7.

[4]. Abdenur JE, et al. Aromatic l-aminoacid decarboxylase deficiency: unusual neonatal presentation and additional findings in organic acid analysis. Mol Genet Metab. 2006 Jan;87(1):48-53.

2-氨基-3-(4-羟基-3-甲氧基苯基)丙酸物理化学性质

[ 密度 ]:
1.3±0.1 g/cm3

[ 沸点 ]:
407.3±45.0 °C at 760 mmHg

[ 分子式 ]:
C₁₀H₁₃NO₄

[ 分子量 ]:
211.214

[ 闪点 ]:
200.1±28.7 °C

[ 精确质量 ]:
211.084457

[ PSA ]:
92.78000

[ LogP ]:
0.08

[ 蒸汽压 ]:
0.0±1.0 mmHg at 25°C

[ 折射率 ]:
1.591

[ 储存条件 ]:
室温，密闭，干燥

2-氨基-3-(4-羟基-3-甲氧基苯基)丙酸MSDS

2-氨基-3-(4-羟基-3-甲氧基苯基)丙酸安全信息

[ 风险声明 (欧洲) ]:
22-36/37/38

[ 安全声明 (欧洲) ]:
22-26-36/37/39

[ 危险品运输编码 ]:
NONH for all modes of transport

2-氨基-3-(4-羟基-3-甲氧基苯基)丙酸合成路线

2-氨基-3-(4-羟基-3-甲氧基苯基)丙酸上下游产品

2-氨基-3-(4-羟基-3-甲氧基苯基)丙酸上游产品

2-氨基-3-(4-羟基-3-甲氧基苯基)丙酸下游产品

2-氨基-3-(4-羟基-3-甲氧基苯基)丙酸文献

Cysteinyl-glycine reduction as marker for levodopa-induced oxidative stress in Parkinson's disease patients.

Mov. Disord 26 , 543-546, (2011)

Oxidative stress is influenced by the thiol homeostasis, which determines the redox milieu. One of its components is Cysteinyl-glycine (Cys-Gly) generation, as its metabolic precursor is the free radi...

Pharmacokinetic-pharmacodynamic modeling of levodopa in patients with advanced Parkinson disease.

Clin. Neuropharmacol. 33(3) , 135-41, (2010)

The aims of the present study were to investigate the pharmacokinetic and pharmacodynamic (pk/pd) relationship of levodopa (l-dopa) in patients with advanced Parkinson disease (PD) and also to evaluat...

Levodopa infusion combined with entacapone or tolcapone in Parkinson disease: a pilot trial.

Eur. J. Neurol. 19(6) , 820-6, (2012)

Catechol-O-methyltransferase inhibitors may be used to decrease levodopa requirement. The objective was to investigate whether the levodopa/carbidopa intestinal gel infusion dose can be reduced by 20%...

更多文献